Recently we have identified mRNA encoding a hitherto unknown mammalian X,K-ATPase ␤-subunit expressed predominantly in muscle tissue (Pestov, N. B. et al. (1999) FEBS Lett. 456, 243-248). Here we demonstrate the existence of the predicted protein, designated as ␤ m (␤ muscle ), in human adult skeletal muscle membranes using immunoblotting with ␤ m -specific antibodies generated against recombinant polypeptide formed by extramembrane ␤ m domains. The electrophoretic mobility of ␤ m was shown to be abnormally low due to the presence of Glu-rich sequences. In contrast to mature forms of other known X,K-ATPase ␤-subunits, carbohydrate moiety of ␤ m is sensitive to endoglycosidase H and appears to be composed of short high-mannose or hybrid N-glycans. This finding argues in favor of an intracellular location of ␤ m in human skeletal muscle.
In our previous paper we described homologous human and rat cDNAs encoding a novel X,K-ATPase ␤-subunit (4). RT-PCR showed that the corresponding gene has a highly specific expression pattern being active only in skeletal muscle and at a low level in heart, and silent in other tissues tested. To emphasize this remarkable tissue specificity that is in sharp contrast with other ␤-subunit isoforms the novel protein was named as muscle-specific X,K-ATPase ␤-subunit, or ␤ m .
Mammalian X,K-ATPase ␤-subunit proteins are readily discernable by the presence of specific conserved sequence motifs, e.g., Y(Y/F)PYYGK. The topology of the proteins features one transmembrane stretch and a C-terminal ectodomain that is modified by N-glycosylation at several sites (5, 6) . The deduced primary structure of ␤ m is similar to other isoforms in these respects, but the protein is unique in the X,KATPase family due to an extension of its N-terminus that is rich in glutamic acid residues (4) . In addition, ␤ m provides the only known example of alternative splicing among the mammalian X,K-ATPase ␤-subunit mRNAs. Two ␤ m transcripts that differ in the presence or absence of a 12-bp sequence are created through the use of two donor 5Ј-sites in intron 2 (4). These variants encode two proteins of 357 and 353 amino acid residues that differ in four residues in the junction between cytoplasmic and intramembrane domains.
Here we report the production of a recombinant ␤ m protein and specific antibodies, the demonstration of the existence of the predicted ␤ m protein in human skeletal muscle membranes, and evidence that ␤ m is different from other X,K-ATPase ␤-subunits in the glycosylation status.
MATERIALS AND METHODS
DNA constructs. Conditions of RT-PCR were described before (7) with the exception that Pfu DNA polymerase (Promega) was used instead of Taq. PCR products of primers PU (caatgcctgsgtggcagaaattgcagatc) and TU (agatgatcggctgtcttagatgtcc) representing frag-ments from Asn80 to C-end (Thr357) were cloned into pCR-Script Amp vector using PCR-Script Amp cloning kit (Stratagene). Among the colonies, constructs pH3, pH21, and pH31 were identified that comprised alternatively spliced transcripts A, B, and a transcript lacking exon 3 (hereafter called C), respectively (Fig. 1) . To restore the complete reading frame, product of primers VEKO1 (cttkgcccactgaacagccatgag) and BS1 (ggcgaagggtctgatcataac) (corresponding to Met1-Ala160) was cloned as above and the PstI-BamHI cassette from this construct was introduced in the plasmids pH3, pH21, and pH31 to give constructs pHP3, pHP21, and pHP31, respectively. These plasmids contained the ORFs (1071 bp, variant A; 1059 bp variant B; 942 bp, variant C) plus 129 bp from 3Ј-UTR, and 19 bp from 5Ј-UTR. For protein expression, full-length coding region of pHP31, was amplified with primers F2SWHBGL (gaacaagatctagaaggcarctccggtcca) and BCHINR (tgaaaagcttargtttctatgttcagggt), digested with BglII plus HindIII and cloned at BamHI/HindII sites of vector pQE30 (Qiagen) to give an expression construct, pH3130.
Preparation of recombinant protein and ␤ m -specific antibodies. JM109 Escherichia coli cells harboring the pH3130 plasmid were grown at 37°C in LB medium supplemented with 100 mg/l ampicillin, 5 mM MgCl 2 and 5 mM CaCl 2 until A 600 0.5. Then 1 mM isopropyl-␤-D-thiogalactopyranoside was added and growing continued for 4 h. The cells were pelleted and the transmembrane moietydeficient ␤ m protein was purified by immobilized metal affinity chromatography as described before (8) . For immunization of rabbits a previously described schedule (9) was modified so that a nitrocellulose-absorbed antigen (see (10) for preparation) was used for booster injections. Affinity purification of antibodies was performed using the antigen blotted onto PVDF membrane essentially as described (11) .
Tissues and preparation of microsomes. Tissues were from 50 -60-year-old female donors. Samples of human skeletal and heart muscles were provided by Cooperative Human Tissue Network (Columbus, OH) and brain from Harvard Brain Tissue Resource Center (Belmont, MA). Tissue samples (3 g) were frozen in liquid nitrogen, crushed with a hammer and homogenized with a Polytron homogenizer at 12000 rpm for 1 min in buffer A (20 ml 30 mM Tris-HCl (pH 8.0), 2 mM EDTA, 100 M PMSF, 0.1% methanol, 5 mM benzamidine, 1 M leupeptin, 1 M pepstatin, 1 M bacitracin). The homogenate was centrifuged at 9000g for 20 min, and the microsomes were pelleted at 150,000g for 30 min. The pellet was washed with the buffer A supplemented with 200 mM NaCl, resuspended in the buffer A containing 10% sucrose and stored at Ϫ70°C.
Deglycosylation and Western blotting. Microsomes containing 60 g protein were incubated at 100°C for 5 min with 0.5% SDS and 1% ␤-mercaptoethanol and placed on ice. Then 1% octyl glucoside, 100 M PMSF, 1* protease inhibitor cocktail (Sigma) were added and the samples were incubated either with 50 mM sodium citrate (pH 5.5) plus 1000 u Endo H f (New England Biolabs) or with 50 mM sodium phosphate (pH 7.5) plus 500 u PNGase F (New England Biolabs) at 37°C for 1 h. Control samples were incubated without the glycosidases in 50 mM sodium phosphate. The Laemmli sample loading buffer (12) was added and the samples were incubated again at 100°C for 5 min. Then 10 g protein was electrophoresed (12) and blotted onto PVDF membrane (Amersham-Pharmacia). The membrane was blocked in 5% lowfat milk in TBS supplemented with Megablock (Cel Associates) diluted 1:500. Then the membrane was consequently incubated with the affinity purified anti-␤ m rabbit antibodies, biotin conjugated anti-rabbit antibodies (AmershamPharmacia) and streptavidin-peroxidase (Sigma, S9420) for 1 h each with thorough washes in TBS with 0.1% Tween 20 between incubations. The immunoblots were visualized with a chemiluminescent substrate (ECLϩPlus, Amersham-Pharmacia). The same reagents were used for control experiments except that antibodies against Na,K-ATPase ␤2-subunit or affinity purified rabbit antibodies against a non-related hexahistidine-tagged protein were substituted for the anti-␤ m antibodies. 10 kDa protein ladder (Life Technologies) and broad range standards (New England Biolabs) were used for calculation of apparent molecular masses.
RESULTS
In our previous work we reported the primary structure of ␤ m cDNA as determined by direct sequencing of overlapping RT-PCR products (4). Here we have reconstructed full-length ORFs of alternatively spliced transcripts of human ␤ m . Cloning of the PCR product of primers PU and TU allowed the identification of variants A and B (containing or lacking a 12-bp insert, respectively). In addition, despite the use of a gelpurified band for cloning, we also identified another variant with the 12-bp insert but without a 129-bp sequence corresponding to exon 3 (this exon encodes the transmembrane domain of ␤ m ) (Fig. 1) .
It should be stressed that this new variant (termed C) is unlikely to be a PCR or cloning artifact because the deletion exactly coincides with exon-intron boundaries. Moreover, RT-PCR with primers PU and TU produced additional very weak bands of lower molecular masses when using RNA from some human skeletal muscle samples (results not shown). Obviously, variant C is a rare species among the ␤ m transcripts, and can be thought of as a product of aberrant exon skipping. Quite probably, this variant has no functional importance because the deletion of exon 3 ablates the only transmembrane domain that is functionally indispensable in X,K-ATPase ␤-subunits.
To produce recombinant ␤ m proteins in E. coli, we attempted to clone the ORFs into an expression vector, pQE30 that allows production of proteins with N-terminal hexahistidine tag. Only variant C was successfully cloned into that vector (resulting construct pH3130) while no recombinant colonies were obtained for variants A and B. This is possibly due to their severe toxicity to bacteria (a frequent phenomenon for recombinant proteins with hydrophobic segments (9)). However, the toxicity problem was also significant for the C-variant: induction of protein expression from the construct pH3130 resulted in a rapid halt of cell growth. Only trace amount of protein was purified from such cells. Fortunately, it was found that the toxic effect could be diminished by the addition of calcium and magnesium in the medium. In this case only a minor reduction of growth rate after induction was observed and about 2.5 mg protein per liter of culture was purified by immobilized metal affinity chromatography. Such a yield is low in comparison with usual yields of non-toxic proteins (9), however, the amount of the ␤ m protein obtained was sufficient to raise polyclonal antibodies with their subsequent affinity purification.
The mobility of the purified recombinant protein (variant C) in SDS-PAGE corresponds to an apparent molecular mass of 49 kDa (Fig. 2) , that is much higher than calculated from its deduced sequence (38.36 kDa). However, the abnormal electrophoretic mobility corresponding to an apparently higher molecular mass is frequently observed for acidic proteins, especially those with Glu-rich domains. To give just one example, Glurich cyclic nucleotide-gated channel from rod photoreceptors migrates as 240 kDa instead of 155 kDa calculated from cDNA (13).
Microsomes prepared from three different human tissues, skeletal muscle, heart and brain, were analyzed by Western blotting with the affinity purified antibodies against the recombinant ␤ m protein (Fig. 3) . The tissue choice was dictated by previous results on RT-PCR screening of many tissues (4) where ␤ m transcripts were detected only in skeletal and heart muscles. Brain microsomes were taken as a negative control. A specific band was observed in skeletal muscle (Fig. 3, lanes 4 -6) while no specific bands were observed in other tissues (Fig. 3, lanes 1-3 and 7-8) . Thus, the existence of ␤ m protein in human skeletal muscle microsomes was demonstrated, while no protein was detected in microsomes from human heart and brain.
In order to characterize ␤ m protein glycosylation status, the microsome proteins were treated with glycosidases, Endo H and PNGase F. The electrophoretic mo- 
FIG. 2. Electrophoretic analysis of purified recombinant X,K-
ATPase ␤ m -subunit (variant C with N-terminal hexahistidine tag). The protein was purified from E. coli as described under Materials and Methods and subjected to SDS-PAGE (12% polyacrylamide gel with Coomassie blue R staining). Lane 1, molecular mass markers (10 kDa protein ladder, Life Technologies); lane 2, purified recombinant X,K-ATPase ␤ m -subunit (variant C with N-terminal hexahistidine tag). bility of the detected ␤ m protein without deglycosylation corresponds to an apparent molecular mass of 57 kDa (Fig. 3, lane 4 ). Treatment with either Endo H or PNGase F shifted the band mobility indicating that N-glycans on human skeletal muscle ␤ m are sensitive to these glycosidases (Fig. 3, lanes 5 and 6) . Addition of ␣-L-fucosidase to enhance the action of the glycosidases did not change the mobility shifts (results not shown). The electrophoretic mobility of the detected ␤ m protein deglycosylated with PNGase F corresponds to an apparent molecular mass of 52 kDa (Fig. 3, lane 6) . The Endo H treated protein (Fig. 3, lane 5) migrates slightly more slowly so that its molecular mass is 0.5-1.0 kDa higher than that of the PNGase F treated protein.
The apparent molecular mass of the deglycosylated ␤ m protein from human skeletal muscle microsomes (52 kDa) is much higher than calculated values for proteins deduced from cDNA (41.6 kDa, 41.0 kDa, and 36.9 kDa for variants A, B, and C, respectively). However, the difference between the mobilities of the recombinant ␤ m protein (Fig. 2) and the protein detected in skeletal muscle (Fig. 3, lane 4 ) corresponds to about 3 kDa and is close to the difference of their calculated molecular masses of 3.24 kDa (the recombinant ␤ m protein contains 312 amino acid residues from variant C and additional 11 residues encoded by the vector). Therefore, the observed mobility of human skeletal muscle ␤ m corresponds to the value that should be expected from the mobility of the recombinant protein.
The detected ␤ m protein (Fig. 3, lanes 4 -6) can correspond to either A or B splicing variants, or a mixture of them because the difference of their molecular masses (0.65 kDa) is too small for adequate resolution in SDS-PAGE. On the other hand, the mobility of variant C, if it exists in the tissues, is expected to correspond to 47.3 kDa and this indicates that the detected protein does not correspond to the variant C.
In addition, we have excluded the possibility that the bands observed (Fig. 3) were generated by crossreaction of our antibodies with a major skeletal muscle membrane-associated protein, the 53-kDa glycoprotein, that has a similar electrophoretic mobility and similar shifts after Endo H or PNGase F treatments (14, 15) . Specific monoclonal antibodies were used for this purpose (14, 15) . It was found that the 53-kDa glycoprotein migrates close to ␤ m but a difference in their mobilities is readily seen when the samples are run in parallel (results not shown).
The results of Western blotting can be summarized as follows: (i) ␤ m protein is present in human skeletal muscle microsomes; (ii) ␤ m protein was not detected in microsomes from human heart and brain; (iii) ␤ m protein has an abnormal electrophoretic mobility in SDS-PAGE; (iv) detected ␤ m corresponds to either A or B splicing variants, but not to variant C; (v) N-glycans of ␤ m from human skeletal muscle are sensitive to Endo H and PNGase F; and (vi) the electrophoretic mobility shift after deglycosylation indicates that the overall amount of carbohydrate residues is about 5 kDa.
DISCUSSION
Here we have demonstrated for the first time that the previously identified mRNA (4) produces the corresponding protein in human skeletal muscle.
From RT-PCR studies of many rat and human tissues it was found that the ␤ m gene expression is restricted to muscle tissue, the transcripts are abundant in skeletal muscle and are also present in heart, albeit at a much lower level (4) . Immunodetection of the ␤ m protein undertaken in this work was positive only in case of skeletal muscle membranes which produced strong signals in Western blotting with affinity-purified antibodies against recombinant ␤ m . Brain, negative by RT-PCR, was negative also in the immunoblotting as expected, and no ␤ m protein was detected in heart. The latter most possibly indicates that ␤ m protein content is very low in adult human heart, below the detection limit even with the use of a sensitive chemiluminescent substrate. This implies that if heart ␤ m is uniformly distributed in the organ then it is logical to suggest that ␤ m has no functional importance in adult human heart due to its extremely rare abundance. On the other hand, its expression might be restricted to a small population of particular cells (like Na,K-ATPase ␣3 isoform in sites of impulse transmission (16) ). The expression ␤ m in heart may be also upregulated under certain conditions. However, there is no evidence at the moment for such possibilities, and thus ␤ m should be regarded as a skeletal muscle-specific protein.
Despite the fact that ␤ m has an abnormal electrophoretic mobility, it is possible to say that the molecular mass of skeletal muscle ␤ m corresponds to that determined from cDNA because the difference between the mobilities of the purified recombinant and detected deglycosylated proteins closely matches the calculated value. Thus the primary structure of authentic ␤ m from human skeletal muscle was deduced correctly (4), though the existence of minor modifications cannot be excluded.
The most surprising finding was that the difference of electrophoretic mobilities between intact and deglycosylated forms is unexpectedly small. The other known X ϩ ,K ϩ -ATPase ␤-subunits are heavily glycosylated proteins, migrating as fuzzy bands in SDS-PAGE. This usually makes them more difficult to detect by Western blotting and deglycosylation is usually required for high sensitivity of detection in tissues (17, 18) . To give another example, in our control experiments glycosylated Na,K-ATPase ␤2-subunit was detected only in brain (which has a very high content of this isoform) and in all tissues tested after PNGase treatment (not shown). Hence, our results (Fig. 3 ) may be questioned if other ␤ m glycoforms exist in skeletal muscle but were not detected due to the band broadening during electrophoretic separation. This possibility cannot be rigorously excluded, however, in this case the signal from the deglycosylated band should be stronger than from the intact glycoprotein. In fact, densitometry of the images showed that the situation is just the reverse: the band from the intact glycoprotein is slightly stronger than the Endo H or PNGase F treated proteins (results not shown). This indicates that other glycoforms, if present, can constitute only a tiny proportion of total ␤ m , or they contain PNGase F-resistant chains, which are uncommon in mammals. Most likely, the ␤ m protein in human adult skeletal muscle has a glycosylation pattern unusual for the class of X ϩ ,K ϩ -ATPase ␤-subunits. Most of oligosaccharides on other ␤-subunit isoforms are processed to the complex type and are resistant to Endo-H (5, 6, 19, 20, 21) .
How many of the four theoretical N-glycosylation sites in ␤ m are occupied by sugar chains? Because the Endo-H and PNGase F treated proteins have a small but readily detectable difference in their apparent molecular masses and because Endo H leaves only one N-acetylglucosamine residue from the chitobiose core, our guess is that ␤ m is glycosylated at all four sites. The overall sugar content can be estimated about 5 kDa (Fig. 3) and this imposes constraints on the length of the sugar chains. Together with the fact of their sensitivity to Endo-H, it is possible to suggest that ␤ m from adult human skeletal muscle bears short highmannose or hybrid chains.
Other X,K-ATPase ␤-subunit isoforms are plasma membrane proteins and most of their N-glycans are processed to the complex type during transport through the Golgi system, as most glycoproteins that are destined to the cell surface. Only small quantities of high-mannose precursors of the ␤-subunits could be detected (20) . Because ␤ m seems to possess only short high-mannose or hybrid chains it is reasonable to hypothesize that the detected ␤ m protein is not translocated to the plasma membrane but resides in an intracellular compartment of human skeletal muscle cells such as sarcoplasmic reticulum or cis-Golgi.
It is also possible that skeletal muscle has a pool of immature ␤ m whose processing can be stimulated by some exogenous signals. It was shown that insulin treatment or exercise induces translocation of ␣2, ␤1 and ␤2 Na,K-ATPase subunits from intracellular stores to the cell surface in the skeletal muscle (22) (23) (24) . This process may also engage ␤ m and its translocation may be synchronized with the maturation of its sugar chains.
Which catalytic ␣-subunits are associated with ␤ m in skeletal muscle? This problem awaits future investigations, however, it should be noticed that due to its unique structural features (acidic N-terminus and atypical glycosylation) ␤ m cannot be a priori classified as a Na,K-ATPase ␤-subunit. The possibility that it associates with a different P-ATPase cannot be rejected at present especially because there may exist a hitherto unknown muscle-specific X,K-ATPase catalytic ␣-subunit.
